English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

84.1, 89.5). This gain in life expectancy was only partially offset by patients developing RA at a later age. Age at symptom onset was observed to increase linearly by a rate of.16 years (approximately 2 months) per year (t1⁄42.9; P1⁄4 .007)—increasing from 54.2 years in 1986 (95% CI 53.0, 55.1) to 58.5 years in 2012 (95% CI 57.4, 59.6). The excess mortality risk in RA compared with the general population reduced over time. For ERAS the all-cause standardized mortality ratio (SMR) was significantly increased (SMR1⁄41.29; 95% CI 1.20, 1.39), whereas for ERAN it was non-significant (SMR1⁄40.94; 95% CI 0.78, 1.13). A similar trend was observed for cardiovascular mortality, with the SMR reducing from 1.96 (95% CI 1.64, 2.39) in ERAS to 1.11 (95% CI 0.75, 1.46) in ERAN. Conclusion: Life expectancy in RA has increased dramatically over the past 25 years. This may be driven mainly by reductions in excess mortality due to cardiovascular morbidity. Disclosure statement: The authors have declared no conflicts of interest.

rheumatology

O35. Patients Receiving Anti-Tumour Necrosis Factor Therapies Experience Clinically Important Improvements in Rheumatoid Arthritis Related Fatigue: Results from the British Society for Rheumatology Biologics Register